Agios Pharmaceuticals (AGIO) Liabilities and Shareholders Equity (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $1.1 billion in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 24.66% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.0 billion (down 23.23% YoY) and the FY2025 annual result came in at $1.3 billion, down 22.0% from the prior year.
• Liabilities and Shareholders Equity eased to $1.1 billion in Q2 2026, from $1.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.8 billion in Q3 2024 to a low of $773.1 million in Q2 2024.
• A 5-year average of $1.2 billion and a median of $1.2 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 46.32% — and 2025, when it soared 90.31%.
• Tracing AGIO's Liabilities and Shareholders Equity over 5 years: stood at $1.2 billion in 2022, then fell by 24.35% to $937.1 million in 2023, then jumped by 77.48% to $1.7 billion in 2024, then decreased by 22.0% to $1.3 billion in 2025, then decreased by 14.55% to $1.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.